FcγRIII-mediated macrophage phagocytosis emerges as the dominant mechanism of platelet destruction in FNAIT, suggesting targeted receptor blockade could offer a future therapeutic approach, though evidence remains preclinical.

A case-based application of FRESCO trial data positions fruquintinib as a third-line option in KRAS-mutant metastatic colorectal cancer, while emphasizing treatment decisions shift toward disease control and quality of life after multiple prior lines.

A multivariable screening test detects 90% of clinically significant prostate cancers vs 74% with PSA alone, suggesting PSA thresholds may miss aggressive disease despite similar false-positive rates.

A high-sensitivity KRAS-targeted blood test detects residual pancreatic cancer missed by standard assays, suggesting current monitoring approaches may underestimate recurrence risk despite treatment.

US cancer centers are enrolling fewer patients in clinical trials despite continued global therapeutic advances, raising concerns about access, competitiveness, and whether trials are fully integrated into standard oncology care.

A national physician survey found rising intent to leave practice alongside increasing chronic care demands and persistent income stagnation across settings.